The storm before the quiet: Neuronal hyperactivity and Aβ in the presymptomatic stages of Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 1-11

  Stargardt, Anita ^a   Swaab, Dick F ^b   Bossers, Koen ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Alzheimer's disease; A ; Disease progression; Neuronal hyperactivity; Synaptotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN ENZYME; ETIRACETAM; GAMMA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; BRAIN PROTECTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; ENDOCYTOSIS; EPILEPSY; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; HEREDITY; HUMAN; INTRANEURON; MILD COGNITIVE IMPAIRMENT; MOLECULAR BIOLOGY; NERVE CELL; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; ANIMAL; BIOSYNTHESIS; METABOLISM; MOUSE; PATHOLOGY; SECRETION (PROCESS);

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MILD COGNITIVE IMPAIRMENT; NEURONS; PROTEOLYSIS;

EID: 84920411750     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.08.014     Document Type: Review

References (116)

1. Abdul-Hay S.O., Sahara T., McBride M., Kang D., Leissring M.A. Identification of BACE2 as an avid ß-amyloid-degrading protease. Mol. Neurodegener. 2012, 7:46.
2. Alladi S., Bak T.H., Duggirala V., Surampudi B., Shailaja M., Shukla A.K., Chaudhuri J.R., Kaul S. Bilingualism delays age at onset of dementia, independent of education and immigration status. Neurology 2013, 81:1938-1944.
3. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:167-179.
4. Backstrom J.R., Lim G.P., Cullen M.J., Tökés Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J.Neurosci. 1996, 16:7910-7919.
5. Bakker A., Krauss G.L., Albert M.S., Speck C.L., Jones L.R., Stark C.E., Yassa M.A., Bassett S.S., Shelton A.L., Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012, 74:467-474.
6. Basset S.S., Yousem D.M., Cristinzio C., Kusevic I., Yassa M.A., Caffo B.S., Zeger S.L. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain J. Neurol 2006, 129:1229-1239.
7. Benilova I., De Strooper B. Neuroscience. Promiscuous Alzheimer's amyloid: yet another partner. Science 2013, 341:1354-1355.
8. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
9. Birch A.M., McGarry N.B., Kelly A.M. Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus 2013, 23:437-450.
10. Bokde A.L.W., Karmann M., Born C., Teipel S.J., Omerovic M., Ewers M., Frodl T., Meisenzahl E., Reiser M., Möller H.-J., Hampel H. Altered brain activation during a verbal working memory task in subjects with amnestic mild cognitive impairment. J.Alzheimers Dis. 2010, 21:103-118.
11. Bookheimer S., Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu. Rev. Clin. Psychol. 2009, 5:343-362.
12. Bossers K., Wirz K.T.S., Meerhoff G.F., Essing A.H.W., van Dongen J.W., Houba P., Kruse C.G., Verhaagen J., Swaab D.F. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain J. Neurol. 2010, 133:3699-3723.
13. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
14. Briones T.L., Rogozinska M., Woods J. Environmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery. J.Neurotrauma 2009, 26:613-625.
15. Bückig A., Tikkanen R., Herzog V., Schmitz A. Cytosolic and nuclear aggregation of the amyloid beta-peptide following its expression in the endoplasmic reticulum. Histochem. Cell Biol. 2002, 118:353-360.
16. Burke S.N., Barnes C.A. Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 2006, 7:30-40.
17. Busche M.A., Chen X., Henning H.A., Reichwald J., Staufenbiel M., Sakmann B., Konnerth A. Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8740-8745.
18. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.-H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
19. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000, 157:277-286.
20. Celone K.A., Calhoun V.D., Dickerson B.C., Atri A., Chua E.F., Miller S.L., DePeau K., Rentz D.M., Selkoe D.J., Blacker D., Albert M.S., Sperling R.A. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J.Neurosci. 2006, 26:10222-10231.
21. Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
22. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
23. Clayton E.L., Anggono V., Smillie K.J., Chau N., Robinson P.J., Cousin M.A. The phospho-dependent dynamin-syndapin interaction triggers activity-dependent bulk endocytosis of synaptic vesicles. J.Neurosci. 2009, 29:7706-7717.
24. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
25. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
26. Dickerson B.C., Salat D.H., Bates J.F., Atiya M., Killiany R.J., Greve D.N., Dale A.M., Stern C.E., Blacker D., Albert M.S., Sperling R.A. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 2004, 56:27-35.
27. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., Bertram L., Mullin K., Tanzi R.E., Blacker D., Albert M.S., Sperling R.A. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005, 65:404-411.
28. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78:857-902.
29. Du H., Guo L., Yan S.S. Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid. Redox Signal 2012, 16:1467-1475.
30. Dubelaar E.J.G., Mufson E.J., ter Meulen W.G., Van Heerikhuize J.J., Verwer R.W.H., Swaab D.F. Increased metabolic activity in nucleus basalis of Meynert neurons in elderly individuals with mild cognitive impairment as indicated by the size of the Golgi apparatus. J.Neuropathol. Exp. Neurol. 2006, 65:257-266.
31. Durieux A.-C., Prudhon B., Guicheney P., Bitoun M. Dynamin 2 and human diseases. J.Mol. Med. (Berl) 2010, 88:339-350.
32. Eckert M.J., Abraham W.C. Effects of environmental enrichment exposure on synaptic transmission and plasticity in the hippocampus. Curr. Top. Behav. Neurosci. 2013, 15:165-187.
33. Eggermont L.H.P., Swaab D.F., Hol E.M., Scherder E.J.A. Walking the line: a randomised trial on the effects of a short term walking programme on cognition in dementia. J.Neurol. Neurosurg. Psychiatry 2009, 80:802-804.
34. Fragkouli A., Papatheodoropoulos C., Georgopoulos S., Stamatakis A., Stylianopoulou F., Tsilibary E.C., Tzinia A.K. Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over-expressing MMP9. J.Neurochem. 2012, 121:239-251.
35. Fragkouli A., Tzinia A.K., Charalampopoulos I., Gravanis A., Tsilibary E.C. Matrix metalloproteinase-9 participates in NGF-induced α-secretase cleavage of amyloid-β protein precursor in PC12 cells. J.Alzheimers Dis. 2011, 24:705-719.
36. Frykman S., Hur J.-Y., Frånberg J., Aoki M., Winblad B., Nahalkova J., Behbahani H., Tjernberg L.O. Synaptic and endosomal localization of active gamma-secretase in rat brain. PLoS One 2010, 5:e8948.
37. Gerenu G., Dobarro M., Ramirez M.J., Gil-Bea F.J. Early cognitive stimulation compensates for memory and pathological changes in Tg2576 mice. Biochim. Biophys. Acta 2013, 1832:837-847.
38. Ginsberg S.D., Alldred M.J., Counts S.E., Cataldo A.M., Neve R.L., Jiang Y., Wuu J., Chao M.V., Mufson E.J., Nixon R.A., Che S. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 2010, 68:885-893.
39. Grbovic O.M., Mathews P.M., Jiang Y., Schmidt S.D., Dinakar R., Summers-Terio N.B., Ceresa B.P., Nixon R.A., Cataldo A.M. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J.Biol. Chem. 2003, 278:31261-31268.
40. Grienberger C., Rochefort N.L., Adelsberger H., Henning H.A., Hill D.N., Reichwald J., Staufenbiel M., Konnerth A. Staged decline of neuronal function invivo in an animal model of Alzheimer's disease. Nat. Commun. 2012, 3:774.
41. Gyure K.A., Durham R., Stewart W.F., Smialek J.E., Troncoso J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 2001, 125:489-492.
42. Hafez D., Huang J.Y., Huynh A.M., Valtierra S., Rockenstein E., Bruno A.M., Lu B., DesGroseillers L., Masliah E., Marr R.A. Neprilysin-2 is an important β-amyloid degrading enzyme. Am. J. Pathol. 2011, 178:306-312.
43. Hajieva P., Kuhlmann C., Luhmann H.J., Behl C. Impaired calcium homeostasis in aged hippocampal neurons. Neurosci. Lett. 2009, 451:119-123.
44. Hama E., Shirotani K., Iwata N., Saido T.C. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J.Biol. Chem. 2004, 279:30259-30264.
45. Hämäläinen A., Pihlajamäki M., Tanila H., Hänninen T., Niskanen E., Tervo S., Karjalainen P.A., Vanninen R.L., Soininen H. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol. Aging 2007, 28:1889-1903.
46. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schürmann B., Heun R., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hüll M., Rujescu D., Goate A.M., Kauwe J.S.K., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Mühleisen T.W., Nöthen M.M., Moebus S., Jöckel K.-H., Klopp N., Wichmann H.-E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
47. Hersh L.B., Rodgers D.W. Neprilysin and amyloid beta peptide degradation. Curr. Alzheimer Res. 2008, 5:225-231.
48. Holscher C., Gengler S., Gault V.A., Harriott P., Mallot H.A. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 2007, 561:85-90.
49. Huse J.T., Pijak D.S., Leslie G.J., Lee V.M., Doms R.W. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J.Biol. Chem. 2000, 275:33729-33737.
50. Johnson S.C., Schmitz T.W., Moritz C.H., Meyerand M.E., Rowley H.A., Alexander A.L., Hansen K.W., Gleason C.E., Carlsson C.M., Ries M.L., Asthana S., Chen K., Reiman E.M., Alexander G.E. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol. Aging 2006, 27:1604-1612.
51. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
52. Kennedy M.J., Ehlers M.D. Organelles and trafficking machinery for postsynaptic plasticity. Annu. Rev. Neurosci. 2006, 29:325-362.
53. Kessels H.W., Nabavi S., Malinow R. Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4033-4038.
54. Kim M.J., Lee K.M., Son Y.D., Jeon H.A., Kim Y.B., Cho Z.H. Increased basal forebrain metabolism in mild cognitive impairment: an evidence for brain reserve in incipient dementia. J.Alzheimers Dis. 2012, 32:927-938.
55. Kim T., Vidal G.S., Djurisic M., William C.M., Birnbaum M.E., Garcia K.C., Hyman B.T., Shatz C.J. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013, 341:1399-1404.
56. Kinoshita A., Fukumoto H., Shah T., Whelan C.M., Irizarry M.C., Hyman B.T. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J.Cell Sci. 2003, 116:3339-3346.
57. Kircher T.T., Weis S., Freymann K., Erb M., Jessen F., Grodd W., Heun R., Leube D.T. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J.Neurol. Neurosurg. Psychiatry 2007, 78:812-818.
58. Koffie R.M., Hyman B.T., Spires-Jones T.L. Alzheimer's disease: synapses gone cold. Mol. Neurodegener. 2011, 6:63.
59. Kononenko N.L., Diril M.K., Puchkov D., Kintscher M., Koo S.J., Pfuhl G., Winter Y., Wienisch M., Klingauf J., Breustedt J., Schmitz D., Maritzen T., Haucke V. Compromised fidelity of endocytic synaptic vesicle protein sorting in the absence of stonin 2. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E526-E535.
60. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
61. Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fiévet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossù P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanché H., Dartigues J.-F., Tzourio C., Gut I., Van Broeckhoven C., Alpérovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099. European Alzheimer's Disease Initiative Investigators.
62. Lancaster T.M., Baird A., Wolf C., Jackson M.C., Johnston S.J., Donev R., Thome J., Linden D.E.J. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. Eur. Neuropsychopharmacol. 2011, 21:880-884.
63. Landgren S., von Otter M., Palmér M.S., Zetterström C., Nilsson S., Skoog I., Gustafson D.R., Minthon L., Wallin A., Andreasen N., Bogdanovic N., Marcusson J., Blennow K., Zetterberg H., Kettunen P. Anovel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease. J.Neural Transm. 2012, 1996:833-842.
64. Lau P., Bossers K., Janky R., Salta E., Frigerio C.S., Barbash S., Rothman R., Sierksma A.S.R., Thathiah A., Greenberg D., Papadopoulou A.S., Achsel T., Ayoubi T., Soreq H., Verhaagen J., Swaab D.F., Aerts S., De Strooper B. Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol. Med. 2013, 5:1613-1634.
65. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M.Y., Hersh L.B., Sapolsky R.M., Mirnics K., Sisodia S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
66. Li M., Chen L., Lee D.H.S., Yu L.C., Zhang Y. The role of intracellular amyloid beta in Alzheimer's disease. Prog. Neurobiol. 2007, 83:131-139.
67. Littbrand H., Stenvall M., Rosendahl E. Applicability and effects of physical exercise on physical and cognitive functions and activities of daily living among people with dementia: a systematic review. Am. J. Phys. Med. Rehabil. 2011, 90:495-518.
68. Logothetis N.K., Pauls J., Augath M., Trinath T., Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001, 412:150-157.
69. Machulda M.M., Ward H.A., Borowski B., Gunter J.L., Cha R.H., O'Brien P.C., Petersen R.C., Boeve B.F., Knopman D., Tang-Wai D.F., Ivnik R.J., Smith G.E., Tangalos E.G., Jack C.R. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 2003, 61:500-506.
70. Mackenzie I.R., Miller L.A. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994, 87:504-510.
71. Malinow R., Malenka R.C. AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 2002, 25:103-126.
72. Malito E., Hulse R.E., Tang W.-J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 2008, 65:2574-2585.
73. Marr R.A., Guan H., Rockenstein E., Kindy M., Gage F.H., Verma I., Masliah E., Hersh L.B. Neprilysin regulates amyloid Beta peptide levels. J.Mol. Neurosci. 2004, 22:5-11.
74. Merlo S., Sortino M.A. Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation. Mol. Cell Neurosci. 2012, 49:423-429.
75. Michaluk P., Kolodziej L., Mioduszewska B., Wilczynski G.M., Dzwonek J., Jaworski J., Gorecki D.C., Ottersen O.P., Kaczmarek L. Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J.Biol. Chem. 2007, 282:16036-16041.
76. Newpher T.M., Ehlers M.D. Glutamate receptor dynamics in dendritic microdomains. Neuron 2008, 58:472-497.
77. Nithianantharajah J., Hannan A.J. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat. Rev. Neurosci. 2006, 7:697-709.
78. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
79. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66:435-440.
80. Petrella J.R., Krishnan S., Slavin M.J., Tran T.-T.T., Murty L., Doraiswamy P.M. Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology 2006, 240:177-186.
81. Pihlajamäki M., Jauhiainen A.M., Soininen H. Structural and functional MRI in mild cognitive impairment. Curr. Alzheimer Res. 2009, 6:179-185.
82. Prvulovic D., Van de Ven V., Sack A.T., Maurer K., Linden D.E.J. Functional activation imaging in aging and dementia. Psychiatry Res. 2005, 140:97-113.
83. Putcha D., Brickhouse M., O'Keefe K., Sullivan C., Rentz D., Marshall G., Dickerson B., Sperling R. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J.Neurosci. 2011, 31:17680-17688.
84. Puzzo D., Arancio O. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?. J.Alzheimers Dis 2013, 33(Suppl 1):S111-S120.
85. Puzzo D., Privitera L., Fa' M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M., Jung S.S., Palmeri A., Arancio O. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 2011, 69:819-830.
86. Quiroz Y.T., Budson A.E., Celone K., Ruiz A., Newmark R., Castrillón G., Lopera F., Stern C.E. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann. Neurol. 2010, 68:865-875.
87. Rajendran L., Honsho M., Zahn T.R., Keller P., Geiger K.D., Verkade P., Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11172-11177.
88. Rudinskiy N., Hawkes J.M., Betensky R.A., Eguchi M., Yamaguchi S., Spires-Jones T.L., Hyman B.T. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat. Neurosci. 2012, 15:1422-1429.
89. Sanchez P.E., Zhu L., Verret L., Vossel K.A., Orr A.G., Cirrito J.R., Devidze N., Ho K., Yu G.-Q., Palop J.J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2895-E2903.
90. Schmitz A., Schneider A., Kummer M.P., Herzog V. Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic 2004, 5:89-101.
91. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J.Neurosci. 2007, 27:2866-2875.
92. Shen J., Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:403-409.
93. Stargardt A., Gillis J., Kamphuis W., Wiemhoefer A., Kooijman L., Raspe M., Benckhuijsen W., Drijfhout J.W., Hol E.M., Reits E. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models. Aging Cell 2013, 12:499-507.
94. Stern Y. Cognitive reserve. Neuropsychologia 2009, 47:2015-2028.
95. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
96. Sudoh S., Frosch M.P., Wolf B.A. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002, 41:1091-1099.
97. Szklarczyk A., Lapinska J., Rylski M., McKay R.D.G., Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J.Neurosci. 2002, 22:920-930.
98. Tampellini D., Rahman N., Gallo E.F., Huang Z., Dumont M., Capetillo-Zarate E., Ma T., Zheng R., Lu B., Nanus D.M., Lin M.T., Gouras G.K. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J.Neurosci. 2009, 29:9704-9713.
99. Tebar F., Bohlander S.K., Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol. Biol. Cell 1999, 10:2687-2702.
100. Thom M., Liu J.Y.W., Thompson P., Phadke R., Narkiewicz M., Martinian L., Marsdon D., Koepp M., Caboclo L., Catarino C.B., Sisodiya S.M. Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. Brain J. Neurol. 2011, 134:2969-2981.
101. van der Sluijs P., Hoogenraad C.C. New insights in endosomal dynamics and AMPA receptor trafficking. Semin. Cell Dev. Biol. 2011, 22:499-505.
102. Verret L., Mann E.O., Hang G.B., Barth A.M.I., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A.C., Mody I., Mucke L., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.
103. Vossel K.A., Beagle A.J., Rabinovici G.D., Shu H., Lee S.E., Naasan G., Hegde M., Cornes S.B., Henry M.L., Nelson A.B., Seeley W.W., Geschwind M.D., Gorno-Tempini M.L., Shih T., Kirsch H.E., Garcia P.A., Miller B.L., Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013, 70:1158-1166.
104. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation invivo. Nature 2002, 416:535-539.
105. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
106. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today 2006, 11:931-938.
107. Wei W., Nguyen L.N., Kessels H.W., Hagiwara H., Sisodia S., Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 2010, 13:190-196.
108. Wilson R.S., Mendes De Leon C.F., Barnes L.L., Schneider J.A., Bienias J.L., Evans D.A., Bennett D.A. Participation in cognitively stimulatingactivities and risk of incident Alzheimer disease. JAMA 2002, 287:742-748.
109. Wirths O., Multhaup G., Czech C., Blanchard V., Moussaoui S., Tremp G., Pradier L., Beyreuther K., Bayer T.A. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001, 306:116-120.
110. Wu J., Petralia R.S., Kurushima H., Patel H., Jung M., Volk L., Chowdhury S., Shepherd J.D., Dehoff M., Li Y., Kuhl D., Huganir R.L., Price D.L., Scannevin R., Troncoso J.C., Wong P.C., Worley P.F. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell 2011, 147:615-628.
111. Wu F., Yao P.J. Clathrin-mediated endocytosis and Alzheimer's disease: an update. Ageing Res. Rev. 2009, 8:147-149.
112. Xu W., Yu J.T., Tan M.S., Tan L. Cognitive Reserve and Alzheimer's disease. Mol. Neurobiol. 2014, [Epub ahead of print].
113. Yan P., Hu X., Song H., Yin K., Bateman R.J., Cirrito J.R., Xiao Q., Hsu F.F., Turk J.W., Xu J., Hsu C.Y., Holtzman D.M., Lee J.M. Matrix metalloproteinase-9 degrades amyloid-beta fibrils invitro and compact plaques in situ. J.Biol. Chem. 2006, 281:24566-24574.
114. Yang A.J., Chandswangbhuvana D., Margol L., Glabe C.G. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J.Neurosci. Res. 1998, 52:691-698.
115. Yassa M.A., Stark S.M., Bakker A., Albert M.S., Gallagher M., Stark C.E.L. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage 2010, 51:1242-1252.
116. Youmans K.L., Tai L.M., Kanekiyo T., Stine W.B., Michon S.-C., Nwabuisi-Heath E., Manelli A.M., Fu Y., Riordan S., Eimer W.A., Binder L., Bu G., Yu C., Hartley D.M., LaDu M.J. Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol. Neurodegener. 2012, 7:8.